NASDAQ:ICCC

ImmuCell Stock Forecast, Price & News

$9.72
-0.32 (-3.19 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.72
$10.18
50-Day Range
$8.50
$10.95
52-Week Range
$4.38
$13.20
Volume7,258 shs
Average Volume34,153 shs
Market Capitalization$75.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.9
30 days | 90 days | 365 days | Advanced Chart
Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.


About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

899th out of 2,097 stocks

Diagnostic Substances Industry

17th out of 35 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

Is ImmuCell a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ImmuCell stock.
View analyst ratings for ImmuCell
or view top-rated stocks.

What stocks does MarketBeat like better than ImmuCell?

Wall Street analysts have given ImmuCell a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmuCell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ImmuCell?

ImmuCell saw a increase in short interest in May. As of May 28th, there was short interest totaling 14,600 shares, an increase of 31.5% from the May 13th total of 11,100 shares. Based on an average daily trading volume, of 14,200 shares, the short-interest ratio is presently 1.0 days. Approximately 0.3% of the company's stock are short sold.
View ImmuCell's Short Interest
.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for ImmuCell
.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) released its quarterly earnings results on Thursday, May, 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.05 by $0.11. The biotechnology company earned $4.11 million during the quarter. ImmuCell had a negative trailing twelve-month return on equity of 4.77% and a negative net margin of 9.22%.
View ImmuCell's earnings history
.

How has ImmuCell's stock been impacted by COVID-19 (Coronavirus)?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ICCC shares have increased by 126.0% and is now trading at $9.72.
View which stocks have been most impacted by COVID-19
.

What guidance has ImmuCell issued on next quarter's earnings?

ImmuCell issued an update on its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $4.10 million-$4.10 million, compared to the consensus revenue estimate of $5.40 million.

What price target have analysts set for ICCC?

1 brokerages have issued twelve-month target prices for ImmuCell's stock. Their forecasts range from $14.00 to $14.00. On average, they expect ImmuCell's share price to reach $14.00 in the next year. This suggests a possible upside of 44.0% from the stock's current price.
View analysts' price targets for ImmuCell
or view top-rated stocks among Wall Street analysts.

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 60, Pay $354.27k)
  • Dr. Joseph H. Crabb Ph.D., VP & Chief Scientific Officer (Age 66, Pay $54.98k)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 44, Pay $314.8k)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 65, Pay $255.65k)
  • Elizabeth S. Toothaker, Director of Fin. & Admin.
  • Mr. A. Gustavo Scaffa, Sr. Director of Quality
  • John W. Zinckgraf, Director of Product Devel.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CorMedix (CRMD), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.42%), Morgan Stanley (0.71%), Wedge Capital Management L L P NC (0.28%), BlackRock Inc. (0.25%), Shufro Rose & Co. LLC (0.25%) and HighTower Advisors LLC (0.20%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche.
View institutional ownership trends for ImmuCell
.

Which institutional investors are selling ImmuCell stock?

ICCC stock was sold by a variety of institutional investors in the last quarter, including Shufro Rose & Co. LLC, Minerva Advisors LLC, Morgan Stanley, and HighTower Advisors LLC.
View insider buying and selling activity for ImmuCell
or view top insider-selling stocks.

Which institutional investors are buying ImmuCell stock?

ICCC stock was acquired by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, O Shaughnessy Asset Management LLC, Flagship Harbor Advisors LLC, and BlackRock Inc.. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche.
View insider buying and selling activity for ImmuCell
or or view top insider-buying stocks.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $9.72.

How much money does ImmuCell make?

ImmuCell has a market capitalization of $75.19 million and generates $15.34 million in revenue each year. The biotechnology company earns $-1,020,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does ImmuCell have?

ImmuCell employs 52 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

Where are ImmuCell's headquarters?

ImmuCell is headquartered at 56 EVERGREEN DR, PORTLAND ME, 04103.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.